Physician profile
Matthew Krinock
NPI 1952895716
$2,670.82
in general payments reported to CMS, 2019-2025
21 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.36 · 2021: $447 · 2022: $367 · 2023: $402 · 2024: $294 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.85 |
| Education | $136.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $534.84 | 2021-2025 | Ensite, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $329.71 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $256.18 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $205.17 | 2023-2025 | Wegovy |
| Amgen INC. | $184.94 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $164.66 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.63 | 2021-2025 | Jardiance |
| Atricure, INC. | $146.11 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Alnylam Pharmaceuticals INC. | $124.74 | 2022 | |
| Abiomed | $107.14 | 2022 | |
| Impulse Dynamics (USA) INC. | $100.93 | 2021-2023 | Optimizer |
| Boston Scientific Corporation | $60.85 | 2023-2025 | Watchman, Watchman Flx |
| Heartflow, INC. | $53.73 | 2025 | |
| Novartis Pharmaceuticals Corporation | $43.59 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $41.21 | 2024 | Opsumit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $37.63 | 2024 | |
| Medicomp INC | $34.59 | 2025 | Telepatch Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $29.35 | 2024-2025 | Farxiga |
| Pfizer INC. | $23.05 | 2025 | |
| Medtronic, INC. | $21.63 | 2024 | Linq II |
| Teleflex LLC | $13.14 | 2023 | Guideliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Krinock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.